% | $
Quotes you view appear here for quick access.

công ty Questcor Pharmaceuticals Message Board

  • pharmaman58 pharmaman58 Oct 19, 2012 6:56 AM Flag

    anybody notice this in the Street downgrade?

    Below is the editor's note pasted from the downgrade article--basically saying that no human takes responsibility for the article content because ratings are established by computer. YOU CAN'T MAKE THIS STUFF UP.

    My take? Cramer is practicing the new formula--create a platform, make yourself into a good enough showman to build a following of retail investors, then take their money. These are the P.T. Barnum's of our digital age.

    Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.


    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Anyone who can’t see this as desperation by Citron shouldn’t be in the market.

      Sentiment: Strong Buy

    • Do you realize TheStreet had a BUY on Questcor at $54.40 and the stock fell to $35 in two weeks after they posted this on July 9, 2012?

      TheStreet Wire
      Questcor Reaches New 52-Week High (QCOR)
      By TheStreet Wire 07/09/12 - 10:18 AM EDT
      Find out if (QCOR) is in Cramer's Portfolio.
      NEW YORK (TheStreet) -- Questcor Pharmaceuticals (Nasdaq:QCOR) hit a new 52-week high Monday as it is currently trading at $54.34, above its previous 52-week high of $54.30 with 1.1 million shares traded as of 9:55 a.m. ET. Average volume has been 1.9 million shares over the past 30 days.

      Questcor has a market cap of $3.22 billion and is part of the health care sector and drugs industry. Shares are up 20.8% year to date as of the close of trading on Friday.

      Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. The company has a P/E ratio of 31.5, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

      ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!
      TheStreet Ratings rates Questcor as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full Questcor Ratings Report.

      See all 52-week high stocks or get investment ideas from our investment research center.

    • Do you notice there is no author? Do you realize they don't give any reason for the downgrade other than the stock is down for the year?